George Carrum

researcher

George Carrum is …
instance of (P31):
humanQ5

P106occupationresearcherQ1650915

Reverse relations

author (P50)
Q34273968Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.
Q45419330Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma
Q46561276Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients
Q34876434CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Q48034648Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis
Q104059773Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS post-allogeneic transplant
Q37042225Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Q45864372Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia
Q36941738Comparison of two CD40-ligand/interleukin-2 vaccines in patients with chronic lymphocytic leukemia
Q36059593Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
Q36399791Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease
Q59351745EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation
Q52598637High Incidence of Autoimmune Disease after Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease.
Q35848688Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation.
Q57493527In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas
Q37263151Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
Q45862722Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals
Q40092234Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation
Q42678254Selective depletion of a minor subpopulation of B-chronic lymphocytic leukemia cells is followed by a delayed but progressive loss of bulk tumor cells and disease regression
Q45880996Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabine
Q35068768Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins
Q98164177The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma
Q47218634Tumor-Specific T-Cells Engineered to Overcome Tumor Immune Evasion Induce Clinical Responses in Patients With Relapsed Hodgkin Lymphoma
Q37707135Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity.

Search more.